{"filing":{"accession_number":"0001437749-26-030073","cik":"0001053691","ticker":"CRVO","company_name":"CervoMed Inc.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"crvo20260910_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926030073/crvo20260910_8k.htm"},"events":[{"id":32646,"run_id":30008,"accession_number":"0001437749-26-030073","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"CervoMed announced that initial Phase 2a clinical trial results for neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA) have been accepted for a late-breaking oral presentation at the ISFTD 2026 Annual Meeting in October 2026, with 12-week biomarker data from at least 22 participants to be highlighted. This represents a material clinical development milestone for the company's lead drug candidate, signaling progress in the drug development pipeline and affecting investor assessment of the company's prospects toward potential regulatory approval and commercialization.","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35870,"accession_number":"0001437749-26-030073","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed disclosed that initial Phase 2a clinical trial results for neflamapimod in nfvPPA have been accepted for a late-breaking oral presentation at the ISFTD 2026 conference, with 12-week biomarker data from at least 22 participants to be highlighted. This represents a material clinical development milestone for a clinical-stage biotech company's lead drug candidate, affecting investor assessment of the company's progress toward potential regulatory approval and commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:11:40.029651+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35871,"accession_number":"0001437749-26-030073","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed announced that initial Phase 2a clinical trial results for neflamapimod in nonfluent variant primary progressive aphasia have been accepted as a late-breaking oral presentation at the ISFTD Annual Meeting in October 2026. This represents a material clinical development milestone for a clinical-stage biotech company—acceptance of trial data for presentation at a major scientific conference signals progress in the drug development pipeline and is relevant to investors assessing the company's therapeutic prospects. While not a specific named event type, this is clearly an operational/clinical milestone disclosure rather than a routine administrative matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:11:40.029651+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35870,"accession_number":"0001437749-26-030073","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed disclosed that initial Phase 2a clinical trial results for neflamapimod in nfvPPA have been accepted for a late-breaking oral presentation at the ISFTD 2026 conference, with 12-week biomarker data from at least 22 participants to be highlighted. This represents a material clinical development milestone for a clinical-stage biotech company's lead drug candidate, affecting investor assessment of the company's progress toward potential regulatory approval and commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:11:40.029651+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-09-10"},{"id":35871,"accession_number":"0001437749-26-030073","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed announced that initial Phase 2a clinical trial results for neflamapimod in nonfluent variant primary progressive aphasia have been accepted as a late-breaking oral presentation at the ISFTD Annual Meeting in October 2026. This represents a material clinical development milestone for a clinical-stage biotech company—acceptance of trial data for presentation at a major scientific conference signals progress in the drug development pipeline and is relevant to investors assessing the company's therapeutic prospects. While not a specific named event type, this is clearly an operational/clinical milestone disclosure rather than a routine administrative matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:11:40.029651+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-09-10"}]}